Three years after becoming a standalone consumer healthcare company, Haleon ANZ is entering its next chapter with the roll out of a new global strategy, ‘Win as One’.  

​Haleon’s purpose to “deliver better everyday health with humanity” remains at the centre of its operations. And, to deliver this purpose the company has outlined two ambitions which are to:

• Reach a billion more consumers by 2030
• Generate industry leading shareholder returns

Building on the company’s achievements so far, the ‘Win as One’ strategy is designed to “unlock the full potential” of consumer healthcare in each market. Four new strategic drivers will provide focus for all colleagues globally to deliver these ambitions.  

​Key to delivering the strategy in Australia is Haleon’s commitment to building “superior” brands across the pain relief and oral health categories with “strong performing” brands such as Panadol, Children’s Panadol, Advil, Voltaren (Systemics and Topicals), Sensodyne and Polident.

​Unveiling the new ‘Win as One’ strategy came just prior to Haleon’s three-year anniversary following its demerger with GSK in July 2022.  

​“We’ve come from strong foundations and are proud to have taken that heritage and evolved it to improve the everyday health of Australian consumers, cementing our place in the Australian market,” says Haleon General Manager Anish Patel.

​“Looking back at the Haleon ANZ story over the past three years, we’re thrilled with the progress we’ve made and the lives we have touched through our team, our trusted brands and our investment into research and community. Key to our success has been our partnership with the pharmacy and retailer communities. I would like to acknowledge them and recognise the value we place on our relationships with them.”